ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 7ÔÂ30ÈÕ£¬£¬£¬£¬£¬¾ÝCDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬ÆÕÃ×˹ÉúÎï¼¼Êõ£¨Ö麣£©ÓÐÏÞ¹«Ë¾µÄPM1032×¢ÉäÒº»ñÅúÁÙ´²ÊÔÑéĬʾÔÊÐí¡£¡£¡£¡£¡£PM1032ÊÇÒ»¿îͬʱ°ÐÏòCLDN18.2ºÍ4-1BBµÄË«ÌØÒìÐÔ¿¹ÌåºòѡҩÎ£¬£¬£¬£¬ÄâÓÃÓÚÁªºÏ»¯ÁÆÖÎÁƾֲ¿ÍíÆÚ/×ªÒÆÐÔÒÈÏÙ°©¡£¡£¡£¡£¡£
2. 8ÔÂ1ÈÕ£¬£¬£¬£¬£¬CDE ¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬ÐÅ´ïÉúÎïÂêÊ˶ÈëÄ×¢ÉäÒºµÄÐÂ˳Ӧ֢É걨ÉÏÊУ¬£¬£¬£¬£¬²¢»ñµÃÊÜÀí¡£¡£¡£¡£¡£ÂêÊ˶ÈëÄÊÇÒ»ÖÖ GLP-1R/GCGR Ë«ÖØ¼¤¶¯¼Á£¬£¬£¬£¬£¬Æä·ÊÅÖÖ¢ÉÏÊÐÉêÇëÒÑÓÚ½ñÄê 2 Ô»ñ CDE ÊÜÀí¡£¡£¡£¡£¡£Æ¾Ö¤ÐÅ´ïÉúÎï¹ûÈ»×ÊÁÏ£¬£¬£¬£¬£¬¸ÃÒ©±¾´ÎÉ걨µÄÐÂ˳Ӧ֢Ϊ 2 ÐÍÌÇÄò²¡¡£¡£¡£¡£¡£
3. 7ÔÂ30ÈÕ£¬£¬£¬£¬£¬Ç¿ÉúÐû²¼£¬£¬£¬£¬£¬ÃÀ¹ú FDA Åú×¼ DARZALEX FASPRO?£¨´ïÀ×Í×Óȵ¥¿¹ºÍ͸Ã÷ÖÊËáø-fihj£©ÓëÅðÌæ×ôÃס¢À´ÄǶȰ·ºÍµØÈûÃ×ËÉ (D-VRd) ÁªÊÊÓÃÓÚÐÂÕï¶ÏµÄ¶à·¢ÐÔ¹ÇËèÁö (NDMM) »¼ÕßµÄÓÕµ¼ºÍÀο¿ÖÎÁÆ£¬£¬£¬£¬£¬ÕâЩ»¼ÕßÊʺϽÓÊÜ×ÔÌå¸Éϸ°ûÒÆÖ² (ASCT)¡£¡£¡£¡£¡£
4. 8ÔÂ1ÈÕ£¬£¬£¬£¬£¬CDEÍøÕ¾ÏÔʾ£¬£¬£¬£¬£¬Õý´óÌìÇçÁ½¿îÐÂÒ©±´ÄªËհݵ¥¿¹¡¢°²ÂÞÌæÄὺÄÒÐÂ˳Ӧ֢ÉÏÊÐÉêÇë»ñµÃÊÜÀí£¬£¬£¬£¬£¬ÍƲⱾ´ÎÉ걨ÉÏÊеÄÐÂ˳Ӧ֢ΪһÏßÖÎÁÆÍíÆÚ²»¿ÉÇгý»ò×ªÒÆÐÔÉöϸ°û°©£¨RCC£©Ò»ÏßÖÎÁÆÉöϸ°û°©¡£¡£¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬£¬£¬Éñ¼Ã²ý»ª£¨±±¾©£©ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾ÀÖ³ÉÍê³ÉÁ˽üÒÚÔªPre-AÂÖÈÚ×Ê£¬£¬£¬£¬£¬±¾ÂÖÈÚ×ÊÓÉÖйشå×ÊÔ´ÊÂͶ£¬£¬£¬£¬£¬Öв©¾ÛÁ¦¡¢´«»¯×ÊÔ´ºÍÈýÃÀͶ×ʸúͶ¡£¡£¡£¡£¡£±¾ÂÖËùÈÚ×ʽð½«Ö÷ÒªÓÃÓÚÉñ¼Ã²ý»ªÊ׸ö¹ÜÏßSNUG01µÄINDÉ걨¼°ÆäËû¹ÜÏß²úÆ·µÄÍÆ½øµÈ¡£¡£¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬£¬£¬Öйú¿ÆÑ§ÔºÉúÎïÎïÀíÑо¿ËùÕÔÑÒÍŶÓÓ뵤Âó¸ç±¾¹þ¸ù´óѧClaus LolandÍŶÓÏàÖú£¬£¬£¬£¬£¬ÔÚ¡¶×ÔÈ»¡·ÆÚ¿¯½ÒÏþÂÛÎÄ£¬£¬£¬£¬£¬Í¨¹ýµ¥¿ÅÁ£Àä¶³µç¾µ¼¼ÊõÆÊÎöÁËÈËÔ´È¥¼×ÉöÉÏÏÙËØ×ªÔËÌåÔÚδÁ¬Ïµµ×ÎNETapo£©£¬£¬£¬£¬£¬Á¬Ïµµ×ÎïÈ¥¼×ÉöÉÏÏÙËØ£¨NETNA£©¡¢Á¬ÏµÓóÂݶ¾ËئÖ-MrlAÀàËÆÎNETMrlA£©¡¢Á¬Ïµ°²·ÇËûͪ£¨NETBPP£©£¬£¬£¬£¬£¬ÒÔ¼°Á¬Ïµ¿¹¾«ÉñÆÆËéÖ¢Ò©ÎïÆëÀÎ÷ͪ£¨NETZPD£©µÄ¸´ºÏÎïµÄ¸ßÇø·ÖÂʽṹ¡£¡£¡£¡£¡£
[1]Tuo Hu et al., Transport and inhibition mechanisms of the human noradrenaline transporter. Nature (2024) Doi: https://doi.org/10.1038/s41586-024-07638-z
Ïà¹ØÐÂÎÅ